Search research articles
Contact Us
Filters
Showing results (611-620 of 738) with videos related to
Page
of 74
Sort By:
The Lancet. Diabetes & Endocrinology
|
October 16, 2020
Effects of canagliflozin on anaemia in patients with type 2 diabetes and chronic kidney disease: a post-hoc analysis from the CREDENCE trial
Megumi Oshima, Brendon L Neuen, Meg J Jardine, et al.
Circulation
|
December 14, 2021
Effect of the Glucagon-Like Peptide-1 Receptor Agonists Semaglutide and Liraglutide on Kidney Outcomes in Patients With Type 2 Diabetes: Pooled Analysis of SUSTAIN 6 and LEADER
Ahmed M Shaman, Stephen C Bain, George L Bakris, et al.
Diabetes Care
|
January 21, 2022
Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes According to Baseline HbA1c and Insulin Use: An Analysis From the FIDELIO-DKD Study
Peter Rossing, Ellen Burgess, Rajiv Agarwal, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation
|
April 11, 2008
Prevalence and associations of anemia of CKD: Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES) 1999-2004
Samy I McFarlane, Shu-Cheng Chen, Adam T Whaley-Connell, et al.
Journal of the American Society of Nephrology : JASN
|
September 23, 2021
Early Response in Albuminuria and Long-Term Kidney Protection during Treatment with an Endothelin Receptor Antagonist: A Prespecified Analysis from the SONAR Trial
Hiddo J L Heerspink, Di Xie, George Bakris, et al.
ESC Heart Failure
|
September 3, 2024
Finerenone and left ventricular hypertrophy in chronic kidney disease and type 2 diabetes
Gerasimos Filippatos, Stefan D Anker, George L Bakris, et al.
Blood Pressure
|
June 24, 2008
Predictors of blood pressure response to intensified and fixed combination treatment of hypertension: the ACCOMPLISH study
Sverre E Kjeldsen, Kenneth A Jamerson, George L Bakris, et al.
Clinical Kidney Journal
|
April 23, 2024
Validation of the Klinrisk chronic kidney disease progression model in the FIDELITY population
Navdeep Tangri, Thomas Ferguson, Silvia J Leon, et al.
Kidney International Reports
|
January 10, 2022
Finerenone in Predominantly Advanced CKD and Type 2 Diabetes With or Without Sodium-Glucose Cotransporter-2 Inhibitor Therapy
Peter Rossing, Gerasimos Filippatos, Rajiv Agarwal, et al.
American Heart Journal
|
February 7, 2012
Management of cardiac toxicity in patients receiving vascular endothelial growth factor signaling pathway inhibitors
Richard M Steingart, George L Bakris, Helen X Chen, et al.
Page
of 74
Search research articles
Search
Showing results (611-620 of 738) with videos related to
Sort By:
Page
of 74
The Lancet. Diabetes & Endocrinology
|
October 16, 2020
Effects of canagliflozin on anaemia in patients with type 2 diabetes and chronic kidney disease: a post-hoc analysis from the CREDENCE trial
Megumi Oshima, Brendon L Neuen, Meg J Jardine, et al.
Circulation
|
December 14, 2021
Effect of the Glucagon-Like Peptide-1 Receptor Agonists Semaglutide and Liraglutide on Kidney Outcomes in Patients With Type 2 Diabetes: Pooled Analysis of SUSTAIN 6 and LEADER
Ahmed M Shaman, Stephen C Bain, George L Bakris, et al.
Diabetes Care
|
January 21, 2022
Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes According to Baseline HbA1c and Insulin Use: An Analysis From the FIDELIO-DKD Study
Peter Rossing, Ellen Burgess, Rajiv Agarwal, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation
|
April 11, 2008
Prevalence and associations of anemia of CKD: Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES) 1999-2004
Samy I McFarlane, Shu-Cheng Chen, Adam T Whaley-Connell, et al.
Journal of the American Society of Nephrology : JASN
|
September 23, 2021
Early Response in Albuminuria and Long-Term Kidney Protection during Treatment with an Endothelin Receptor Antagonist: A Prespecified Analysis from the SONAR Trial
Hiddo J L Heerspink, Di Xie, George Bakris, et al.
ESC Heart Failure
|
September 3, 2024
Finerenone and left ventricular hypertrophy in chronic kidney disease and type 2 diabetes
Gerasimos Filippatos, Stefan D Anker, George L Bakris, et al.
Blood Pressure
|
June 24, 2008
Predictors of blood pressure response to intensified and fixed combination treatment of hypertension: the ACCOMPLISH study
Sverre E Kjeldsen, Kenneth A Jamerson, George L Bakris, et al.
Clinical Kidney Journal
|
April 23, 2024
Validation of the Klinrisk chronic kidney disease progression model in the FIDELITY population
Navdeep Tangri, Thomas Ferguson, Silvia J Leon, et al.
Kidney International Reports
|
January 10, 2022
Finerenone in Predominantly Advanced CKD and Type 2 Diabetes With or Without Sodium-Glucose Cotransporter-2 Inhibitor Therapy
Peter Rossing, Gerasimos Filippatos, Rajiv Agarwal, et al.
American Heart Journal
|
February 7, 2012
Management of cardiac toxicity in patients receiving vascular endothelial growth factor signaling pathway inhibitors
Richard M Steingart, George L Bakris, Helen X Chen, et al.
Page
of 74